J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders
2 months, 1 week ago

J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders

Associated Press  

Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by purchasing Intra-Cellular Therapies. Intra-Cellular Therapies Inc. makes Caplyta, a once-daily pill for treating adults with schizophrenia and depression tied to bipolar disorder. Wall Street expects sales of the drug to grow past $1 billion next year and top $2.5 billion by 2028, according to the data firm FactSet. Monday’s announcement comes a few days after Intra-Cellular settled a patent lawsuit over when a cheaper, generic version of Caplyta can enter the U.S. market.

Drug  disorders  pay  billion  delving  tied  sales  deal  buys  treatment  intracellular  system  central  version  drug  company  jj  nervous

History of this topic

J&J to pump another $13B into its MedTech business with Shockwave deal
11 months, 2 weeks ago

J&J to pump another $13B into its MedTech business with Shockwave deal

Associated Press  

Johnson & Johnson is pumping more money into heart care with a roughly $13 billion deal for Shockwave Medical, which specializes in technology that helps open clogged arteries. J&J Chief Financial Officer Joseph Wolk told analysts on Friday that the market for this technology is still “in the early days of scaling up.” He said he sees room for more …

J&J sales grow, but strong dollar tugs at expectations
2 years, 5 months ago

J&J sales grow, but strong dollar tugs at expectations

Associated Press  

Johnson & Johnson topped third-quarter expectations thanks to pharmaceutical sales growth, but a strong dollar made the health care giant tread cautiously again with its outlook. J&J on Tuesday narrowed its 2022 forecast and stuck to the midpoint of its previous range after lowering expectations earlier this year due to the impact of currency exchanges. Revenue from the company’s biggest …

J&J to buy Aragon Pharmaceuticals for prostate cancer candidate
11 years, 9 months ago

J&J to buy Aragon Pharmaceuticals for prostate cancer candidate

Live Mint  

New York: Johnson & Johnson, the world’s biggest maker of health-care products, agreed to buy Aragon Pharmaceuticals Inc. and its experimental prostate cancer drug in a deal worth as much as $1 billion. Aragon’s main experimental prostate cancer drug is in the second of three stages usually required for regulatory approvals in the US and may complement Zytiga, the prostate …

Discover Related